Background: Pts with anaplastic lymphoma kinase (ALK)-rearranged NSCLC have benefited from ALK tyrosine kinase inhibitors (TKIs); however, most pts eventually acquire resistance. Identification of resistance mutations informs subsequent therapy but has typically required invasive repeat biopsies. Here, we assessed the utility of ctDNA analysis and the ability to monitor response longitudinally and detect resistance mutations during therapy with ensartinib, a potent second-generation ALK TKI. Conclusions: Overall, the data suggest that plasma ctDNA analysis can potentially identify a subgroup of pts with ALK+ NSCLC who may derive clinical benefit from ensartinib. Furthermore, serial assessments of ctDNA during therapy offer a convenient method to track tumor response and identify the mutational landscape of acquired resistance. READ ARTICLE
Annals of Oncology DOI:10.1093/annonc/mdz063.010
Authors: L. Horn, J. G. Whisenant, H. Wakelee, K. L. Reckamp, H. Qiao, L. Du, J. Hernandez, V. Huang, S. N. Waqar, S. Patel, R. E. Sanborn, T. Shaffer, K. Garg, A. Holzhausen, K. Harrow, C. Liang, L. P. Lim, M. Li, C. M. Lovly
